Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Gain insights into Recursion Pharmaceuticals' Q4 2024 earnings call. Discover clinical advancements, key partnerships, and strategic plans for 2025.

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

AV0328, one of Alopexx’s lead candidates, is a synthetic PNAG vaccine that has completed a phase 1 trial. The biotech is ...

Prior to his time at Intercept, Mr. Durso spent over two decades at Sanofi, where he held multiple senior leadership positions, including Chief Commercial Officer of the Company’s Global Diabetes ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton ...

Suspected UnitedHealthcare CEO assassin Luigi Mangione has a cult following that has not only donated hundreds of thousands to his defense, his supporters are also saying his prosecution for a ...

Whitten confirmed his new role in a message to GeekWire. Whitten was previously CEO of Cruise, the GM-backed self-driving company that recently halted its robotaxi program. Whitten was also CTO at ...

Teva CEO Richard Francis said that he had not expected such a harsh ... On the branded drug Duvakitug, which Teva is developing with Sanofi, for the treatment of ulcerative colitis and Crohn's disease ...

The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control in adults and pediatric patients with diabetes mellitus. The regulatory ...